An Open-Label, Phase II Study to Evaluate the Efficacy and Safety of SCB01A in Subjects With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Failed Platinum-Based Treatment
Latest Information Update: 07 Jun 2023
Price :
$35 *
At a glance
- Drugs SB 01 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors SynCore Biotechnology
- 08 Apr 2019 Status changed to discontinued.
- 16 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 18 Jan 2017 New trial record